Restless Legs Syndrome Risk and Your Genetics

Restless Legs Syndrome Risk is a genetic susceptibility measure for restless legs syndrome (RLS) — a sensorimotor condition in which an irresistible urge to move the legs, particularly at night, disrupts sleep. RLS is substantially heritable, with genome-wide research identifying multiple genomic loci associated with susceptibility. The CITED1 gene, encoding a transcriptional co-activator expressed in the brain, carries the highest-confidence common genetic signal for RLS identified in current fine-mapping analyses. Below: the genetics, the evidence, and practical context.

What is Restless Legs Syndrome Risk?

Restless Legs Syndrome Risk reflects the heritable component of vulnerability to RLS — a condition marked by an uncomfortable urge to move the legs, most disruptive at night and during periods of rest. RLS affects sleep quality, daytime functioning, and quality of life. Multiple independent genetic loci contribute to susceptibility, establishing RLS as a robustly polygenic trait with one of the larger genetic evidence bases among sleep-related conditions.

RLS is estimated to affect 5–10% of the general adult population, with higher prevalence in older age groups and among people with low iron stores. The condition produces sensations in the legs — often described as crawling, tingling, or an overwhelming urge to move — that are partially or fully relieved by movement but return upon rest. These symptoms follow a circadian pattern, worsening in the evening and nighttime hours, disrupting sleep onset and continuity.

The genetics behind Restless Legs Syndrome Risk

Genome-wide research has implicated hundreds of genomic loci in RLS susceptibility, making this one of the more comprehensively studied polygenic sleep conditions. Among these, the locus with the highest fine-mapping confidence score sits near CITED1 (CBP/p300-interacting transactivator with ED-rich tail 1), located on the X chromosome. CITED1 is a transcriptional co-activator that modulates the activity of regulatory complexes in the brain — its precise role in RLS biology is an active area of investigation, but its L2G fine-mapping confidence of 0.93 makes it the most strongly supported common-variant candidate gene for RLS in current analyses.

Multiple independent genomic loci associated with restless legs syndrome have been identified through genome-wide association studies spanning 2007 through 2024, establishing a substantial and well-replicated genetic contribution to this common sleep-related sensorimotor condition.^[1]

Other high-confidence L2G-prioritized genes for RLS include ASPSCR1, involved in vesicular transport pathways critical for neuronal function; SEMA6D, a semaphorin guidance molecule involved in the formation and patterning of neuronal circuits; and BCL11B, a transcription factor essential for specifying neuronal cell types in the brain and spinal cord. The diversity of gene functions across these loci suggests that RLS susceptibility emerges from disruptions across multiple biological pathways rather than a single shared mechanism.

Of the genes with curated function summaries available in the RLS evidence set, ACTN1 (alpha-actinin-1) is an actin-binding cytoskeletal protein expressed in neurons and other cell types. ACTR5 is a component of the Ino80 chromatin-remodeling complex involved in DNA repair and regulation of gene expression. ADAM2 encodes a member of the ADAM metalloprotease family involved in cell surface remodeling.

The genetic architecture of RLS involves hundreds of confirmed loci — reflecting a highly polygenic trait where no single variant dominates, and where the cumulative effect of many common variants shapes susceptibility in a graded, continuous manner.^[5]

The biological pathways linking these diverse genetic signals to RLS symptoms likely converge on brain iron metabolism and dopaminergic signaling. Low brain iron in certain regions — even when systemic iron stores appear adequate — disrupts dopamine function and is consistently observed in RLS neuroimaging studies. Some genetic loci may act by influencing iron transport proteins expressed in the brain, dopamine receptor sensitivity in sensorimotor circuits, or the development of the neuronal populations responsible for leg movement control.

RLS also shows genetic overlap with periodic limb movements in sleep (PLMS), a related condition involving involuntary leg jerks during sleep. Many people with RLS also experience PLMS, and the two conditions share a substantial proportion of their genetic architecture — consistent with shared underlying biology.

What the research says

Research base: Robust. Restless legs syndrome has one of the larger genetic evidence bases among sleep-related conditions, with eight genome-wide studies in the authorized citation set spanning from 2007 through 2024. The 2007 studies (PMIDs 17634447, 17637780) were landmark analyses establishing the first confirmed common-variant loci for RLS using genome-wide methodology. Follow-up studies in 2008, 2011, and 2017 (PMIDs 18660810, 21779176, 29029846) each expanded the list of confirmed loci and refined gene prioritization. More recent analyses in 2020, 2023, and 2024 (PMIDs 33239738, 38839884, 39078117) reflect larger sample sizes and improved statistical methods.

The replication of RLS genetic signals across independent cohorts and across different ancestry groups provides strong evidence that these associations reflect genuine biology rather than statistical artifacts. The growing number of confirmed loci over successive studies reflects continued scientific investment in characterizing this condition, which has historically been underrecognized relative to its prevalence and impact.

RLS genetics demonstrates partial overlap with the genetics of iron metabolism, Parkinson's disease biology, and periodic limb movements — consistent with clinical observations linking these conditions and supporting shared biological pathways. Some RLS loci fall near genes involved in brain iron homeostasis, providing a possible molecular bridge between the genetic architecture and the iron-deficiency biology of RLS symptoms.

How Restless Legs Syndrome Risk affects you

RLS affects sleep onset, sleep continuity, and daytime alertness. People with genetically elevated susceptibility carry biological factors that may lower the threshold at which sensorimotor circuits generate the urge-to-move sensation. Whether symptoms develop and how severe they become depends also on iron status, age, medications, and other physiological factors.

RLS shows a characteristic waxing-and-waning course — symptoms often worsen in middle to older age, and may be dramatically exacerbated by iron deficiency, certain antidepressants (particularly SSRIs and SNRIs), antihistamines, and antinausea medications that block dopamine receptors. People with elevated genetic susceptibility who take these medications may be at greater risk of RLS onset or symptom worsening.

Pregnancy is a recognized trigger for RLS, particularly in the third trimester, likely due to the high iron demands of pregnancy. People with elevated genetic susceptibility may be especially prone to pregnancy-related RLS onset.

The primary quality-of-life impact is through sleep. Chronic sleep disruption from RLS is associated with daytime fatigue, cognitive difficulty, mood effects, and reduced quality of life — consequences that compound over time if the condition is unaddressed. For people with elevated genetic susceptibility, awareness of these connections may support earlier evaluation if symptoms develop.

Working with your Restless Legs Syndrome Risk result

Known modifiers and what research suggests

For people with elevated genetic susceptibility to RLS, several factors are known to influence whether symptoms emerge and how severe they become:

1. Monitor iron status — Low serum ferritin — even within conventional normal ranges — is associated with worsened RLS symptoms. Research supports maintaining ferritin above 75 µg/L in people with active RLS. For those with genetic susceptibility who have not yet developed symptoms, awareness of iron status may be relevant context.
2. Review medications carefully — Several common drug classes are known to trigger or worsen RLS: antidepressants (particularly SSRIs and SNRIs), antipsychotics, antihistamines, and dopamine-blocking antiemetics. People with elevated genetic susceptibility benefit from extra attention to this interaction before starting these medications.
3. Moderate caffeine and alcohol — Both caffeine and alcohol are reported to aggravate RLS symptoms, possibly by affecting dopaminergic and adenosinergic systems involved in symptom generation. Reducing intake — particularly in the evening hours — may reduce symptom frequency.
4. Maintain regular moderate exercise — Physical activity, particularly stretching and light aerobic exercise performed during daylight hours, is consistently reported to reduce RLS symptom severity. Intense late-evening exercise may sometimes worsen symptoms and should be timed accordingly.
5. Prioritize sleep consistency — RLS symptoms are worse with sleep deprivation. Maintaining consistent sleep timing and adequate sleep duration supports the circadian biology underlying sensorimotor control.

Related traits and genes

Restless Legs Syndrome Risk sits within a broader landscape of sleep and neurological traits. Related traits worth exploring include:

• Panic Disorder Risk — another condition in the Mental and Cognitive category, sharing overlap in sleep disruption and nervous-system arousal
• Insomnia Genetic Risk — the heritable component of chronic difficulty initiating or maintaining sleep, which often co-occurs with RLS
• Sleep Chronotype Genetics — genetics of circadian morning/evening preference, linked to broader sleep-quality outcomes

Cross-category connections:

• Iron Metabolism Genetics — genetic factors in iron absorption and transport, with direct relevance to the iron-deficiency biology of RLS
• Dopamine Metabolism Genetics — variants affecting dopamine synthesis and breakdown, relevant to sensorimotor circuit function in RLS

Frequently asked questions

Is restless legs syndrome genetic?

RLS has a strong genetic component. Family studies consistently show that RLS aggregates in families, and twin studies indicate substantial heritability. Having a first-degree relative with RLS roughly doubles risk of the condition. Genome-wide research has identified many independent associated loci confirming the polygenic architecture. The condition is also influenced by iron status, medications, age, and pregnancy, so genetics interacts with these environmental and physiological factors to shape symptom severity and timing.

What genes are linked to restless legs syndrome?

Genome-wide studies have implicated hundreds of genomic regions in RLS susceptibility. Among the highest-confidence loci, the strongest common-variant signal sits near the CITED1 gene — a transcriptional co-activator expressed in the brain. Other high-confidence loci include genes involved in neuronal circuit formation (SEMA6D), neuronal cell-type specification (BCL11B), and vesicular transport (ASPSCR1). The diverse gene functions across these loci suggest RLS susceptibility involves multiple biological pathways.

What does a higher genetic susceptibility score for RLS mean?

A higher score indicates above-average genetic loading for RLS risk based on the pattern of common genetic variants. Many people with elevated genetic susceptibility never develop clinically significant RLS, while others with lower genetic scores do — particularly if environmental factors like iron deficiency or triggering medications are present. Genetic susceptibility describes tendency, not certainty.

What can reduce restless legs syndrome symptoms?

Established approaches include iron supplementation when ferritin is low, avoiding known medication triggers, moderate regular exercise, and caffeine and alcohol reduction. Behavioral approaches such as leg massage, hot baths, and distraction techniques can reduce symptom intensity during episodes. For people with significant or chronic RLS, clinical evaluation is appropriate — effective pharmacological options exist.

Is RLS serious?

RLS is not life-threatening, but chronic sleep disruption from untreated RLS carries meaningful impacts on daytime function, cognitive performance, mood, and quality of life. In many cases, RLS is associated with periodic limb movements in sleep that disrupt sleep further. For many people, RLS is mild and manageable; for others it significantly affects daily functioning. Severity varies with age, iron status, medications, and individual genetics.

References

1. Genome-wide study of restless legs syndrome genetics (2007). PMID: 17634447.
2. Genetic association study establishing common RLS loci (2007). PMID: 17637780.
3. RLS genetic research (2008). PMID: 18660810.
4. Expanded analysis of RLS genetic architecture (2011). PMID: 21779176.
5. Large-scale RLS genome-wide association study (2017). PMID: 29029846.
6. RLS genetics with updated methodology (2020). PMID: 33239738.
7. Recent large-scale RLS genetics analysis (2023). PMID: 38839884.
8. Genome-wide RLS study (2024). PMID: 39078117.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-25)
• Open Targets Platform (CC0 1.0, accessed 2026-05-25)
• ClinVar (NCBI, accessed 2026-05-25) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-25)